Gain Therapeutics

Yahoo Finance • 28 days ago

Wednesday Sector Laggards: Precious Metals, Biotechnology Stocks

In trading on Wednesday, precious metals shares were relative laggards, down on the day by about 2.9%. Helping drag down the group were shares of Avino Silver & Gold Mines, off about 8% and shares of Perpetua Resources down about 7.7% on... Full story

Yahoo Finance • 4 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small m... Full story

Yahoo Finance • 6 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small m... Full story

Yahoo Finance • 6 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® 

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to exposures observed in Phase... Full story

Yahoo Finance • 7 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small... Full story

Yahoo Finance • 7 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled 21 subjects and the last participants wil... Full story

Yahoo Finance • 8 months ago

H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock at $8 price target

Investing.com - H.C. Wainwright has reiterated its Buy rating and $8.00 price target on Gain Therapeutics (NASDAQ:GANX), maintaining its positive outlook on the clinical-stage biotechnology company. Currently trading at $1.97, GANX has sho... Full story

Yahoo Finance • 9 months ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small m... Full story

Yahoo Finance • 9 months ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small m... Full story

Yahoo Finance • 9 months ago

Gain Therapeutics stock falls after announcing public offering

Investing.com -- Gain Therapeutics Inc (NASDAQ:GANX) stock fell 11% after the clinical-stage biotechnology company announced plans for an underwritten public offering of common stock and warrants to purchase common stock. The company, w... Full story

Yahoo Finance • 9 months ago

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small m... Full story

Yahoo Finance • 9 months ago

Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations

Investing.com - Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotech company with a market cap of $48.3 million, announced accelerated enrollment in its Phase 1b clinical study evaluating GT-02287 in Parkinson’s disease patients, re... Full story

Yahoo Finance • 9 months ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enr... Full story

Yahoo Finance • 10 months ago

Gain Therapeutics increases authorized common shares to 100 million after stockholder vote

Gain Therapeutics , Inc. (NASDAQ:GANX) announced Tuesday that it has amended its certificate of incorporation to increase the number of authorized shares of its common stock from 50 million to 100 million. The amendment was filed with the... Full story

Yahoo Finance • 11 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small mo... Full story

Yahoo Finance • last year

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Gain Therapeutics, Inc. (NASDAQ:GANX) stands against other top healthcare stocks t... Full story

Yahoo Finance • last year

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small... Full story

Yahoo Finance • last year

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small... Full story

Yahoo Finance • last year

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small... Full story

Yahoo Finance • last year

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small... Full story